October 9, 2019 Press release - Non-regulatory Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
September 24, 2019 Press release - Non-regulatory Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
July 31, 2019 Press release - Non-regulatory Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC
July 8, 2019 Press release - Regulatory Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma
June 3, 2019 Press release - Non-regulatory Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
May 23, 2019 Press release - Regulatory Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
May 8, 2019 Press release - Non-regulatory Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma
March 19, 2019 Press release - Non-regulatory Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring
March 15, 2019 Press release - Regulatory Targovax signs clinical collaboration agreement with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute
March 14, 2019 Press release - Non-regulatory Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology
March 8, 2019 Press release - Non-regulatory Targovax announces Notice of Allowance in the US on patent covering the TG mutant-RAS neoantigen vaccine platform
February 11, 2019 Press release - Non-regulatory First patient treated in dose expansion cohort of Targovax’s ONCOS-102 trial in melanoma
February 4, 2019 Press release - Non-regulatory Targovax ASA: Announcement of fourth quarter and full year results 2018
January 17, 2019 Press release - Non-regulatory Targovax granted European Patent for mutant-RAS neoantigen platform lead products
